摘要
目的观察吉非替尼(易瑞沙)治疗非小细胞肺癌(NSCLC)复发转移患者的疗效及其毒副反应。方法回顾性研究2007年2月～2010年2月我院各科治疗的非小细胞肺癌术后复发转移患者,分为A、B两组,A组以吉非替尼为二线治疗方案,B组以细胞毒药物作为二线方案而吉非替尼作为三线治疗方案,评价两组患者近期及远期的疗效。结果吉非替尼作为二线治疗方案,其疾病控制率(CR+PR+SD)为73%,有效率(CR+PR)为59%,6个月生存率为86%,1年生存率为45%;作为三线治疗,疾病控制率(CR+PR+SD)为56%,有效率(CR+PR)为38%,6个月生存率为76%,1年生存率为28%。结论对于转移复发非小细胞肺癌患者,尽早应用吉非替尼治疗可以使患者更大获益。
Objective To observe therapeutic effect of gefitinib （ Iressa ） as second-line and third-line treatment in patients with non-small cell lung cancer （ NSCLC ） recurrence and metastasis. Methods Retrospective studies were made on NSCLC cases treated in our hospital from February 2007 to February 2010. 51 patients were divided into A, B two groups. A group accepted the therapy of gefitinib as second-line treatment and B group accepted the therapy of cytotoxic drug as second-line treatment and gefitinib as third- line treatment. The short and long term effects were evaluated. Results In A group, disease control rate was 73%, effective rate was 59%, 6-month survival rate was 86%, 1-year survival rate was 45%. In B group, disease control rate was 56%, effective rate was 38%, 6-month survival rate was 76%, l-year survival rate was 28%. Conclusion For non-small cell lung cancer with metastasis and recurrence in patients, earlier application of gefitinib therapy can benefit patients more.
出处
《中国现代医生》
2011年第21期71-73,共3页
China Modern Doctor
关键词
肿瘤
非小细胞肺癌
吉非替尼
Tumor
Non-small cell lung cancer
Gefitinib
